What is the share price of Gufic Biosciences Ltd (GUFICBIO) today?
The share price of GUFICBIO as on 18th September 2026 is ₹436. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gufic Biosciences Ltd (GUFICBIO) share?
The past returns of Gufic Biosciences Ltd (GUFICBIO) share are- Past 1 week: 3.49%
- Past 1 month: 4.42%
- Past 3 months: 21.91%
- Past 6 months: 44.80%
- Past 1 year: 20.34%
- Past 3 years: 48.38%
- Past 5 years: 123.36%
What are the peers or stocks similar to Gufic Biosciences Ltd (GUFICBIO)?
The peers or stocks similar to Gufic Biosciences Ltd (GUFICBIO) include:What is the dividend yield % of Gufic Biosciences Ltd (GUFICBIO) share?
The current dividend yield of Gufic Biosciences Ltd (GUFICBIO) is 0.02.What is the market cap of Gufic Biosciences Ltd (GUFICBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gufic Biosciences Ltd (GUFICBIO) is ₹4372.32 Cr as of 18th September 2026.What is the 52 week high and low of Gufic Biosciences Ltd (GUFICBIO) share?
The 52-week high of Gufic Biosciences Ltd (GUFICBIO) is ₹467.80 and the 52-week low is ₹268.What is the PE and PB ratio of Gufic Biosciences Ltd (GUFICBIO) stock?
The P/E (price-to-earnings) ratio of Gufic Biosciences Ltd (GUFICBIO) is 68.07. The P/B (price-to-book) ratio is 6.58.Which sector does Gufic Biosciences Ltd (GUFICBIO) belong to?
Gufic Biosciences Ltd (GUFICBIO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gufic Biosciences Ltd (GUFICBIO) shares?
You can directly buy Gufic Biosciences Ltd (GUFICBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gufic Biosciences Ltd
GUFICBIO Share Price
NSE₹436.002.59% (+11.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GUFICBIO Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GUFICBIO Performance & Key Metrics
GUFICBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 59.52 | 6.58 | 0.02% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
GUFICBIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GUFICBIO Company Profile
Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
GUFICBIO Sentiment Analysis
GUFICBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
GUFICBIO Stock Summary · June 2026
Management framed the quarter as top‑line momentum paired with near‑term margin pressure, reporting Q4 revenue of ~INR252 crore and Q4 EBITDA of INR44.7 crore (17.7% margin). Management conveyed a constructive, execution‑focused tone, prioritizing commercialization of owned marketing authorizations internationally, scaling the Indore site (now at ~30% utilization and EBITDA breakeven), deepening backward integration for higher‑value starting materials, and expanding CMO work on GLP‑1 while continuing to strengthen the domestic specialty portfolio. They acknowledged tensions: revenue growth came alongside full‑year bottom‑line compression, ongoing registration and headcount costs that will partly offset margin gains, and substantial past critical‑care receivables that drove a distribution model change and an INR22 crore revenue impact across Q2–Q4. Near term they reiterated specific operational milestones — EU GMP certification expected soon, GLP‑1 validation batches planned for July–August, new product revenue from aztreonam–avibactam beginning in Q1 with greater scale in Q2 — and quantified guidance of targeting overall EBITDA around 18% for FY27 while expecting the receivables situation not to recur.
GUFICBIO Stock Growth Drivers
GUFICBIO Stock Growth Drivers
7Indore facility ramp and CMO-scale advantage
The Indore site has moved from qualification and validation into commercial scale, achieving the year-end
Financial rebound and cleaner runway into FY27
Q4 delivered record operating performance with revenue of ~INR252 crore, EBITDA of INR44.7 crore (17.7%
GUFICBIO Stock Challenges
GUFICBIO Stock Challenges
7Profitability deterioration and margin compression
Despite revenue growth to around INR940.5 crore for the year, the company reported a drop
Investment‑driven cost burden and one‑time P&L hits from capacity build‑out
Heavy recent investment in the new Indore facility and associated capacity build‑out has produced immediate
GUFICBIO Forecast
GUFICBIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GUFICBIO
GUFICBIO
Income
Balance Sheet
Cash Flow
Quarterly Normal View
GUFICBIO Income Statement
GUFICBIO Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 195.87 | 204.07 | 204.29 | 209.66 | 205.41 | 224.65 | 239.17 | 232.20 | 250.65 | 261.28 | ||||||||||
Operating & Other expenses | 160.77 | 167.03 | 165.56 | 173.87 | 178.65 | 190.42 | 199.21 | 198.43 | 204.61 | 214.21 | ||||||||||
EBITDA | 35.10 | 37.04 | 38.73 | 35.79 | 26.76 | 34.23 | 39.96 | 33.77 | 46.04 | 47.07 | ||||||||||
| Depreciation/Amortization | 4.34 | 4.31 | 4.30 | 4.62 | 7.84 | 7.72 | 7.77 | 7.69 | 7.65 | 7.71 | ||||||||||
| PBIT | 30.76 | 32.73 | 34.43 | 31.17 | 18.92 | 26.51 | 32.19 | 26.08 | 38.39 | 39.36 | ||||||||||
| Interest & Other Items | 3.65 | 4.62 | 5.18 | 4.91 | 8.40 | 9.23 | 9.58 | 8.36 | 9.44 | 9.32 | ||||||||||
| PBT | 27.11 | 28.11 | 29.25 | 26.26 | 10.52 | 17.28 | 22.61 | 17.72 | 28.95 | 30.04 | ||||||||||
| Taxes & Other Items | 7.07 | 7.25 | 7.49 | 6.96 | 2.80 | 4.20 | 5.78 | 5.30 | 7.05 | 7.73 | ||||||||||
| Net Income | 20.04 | 20.86 | 21.76 | 19.30 | 7.72 | 13.08 | 16.83 | 12.42 | 21.90 | 22.31 | ||||||||||
| EPS | 2.00 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 |
GUFICBIO Company Updates
GUFICBIO Stock Peers
GUFICBIO Past Performance & Peer Comparison
GUFICBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gufic Biosciences Ltd | 68.07 | 6.58 | 0.02% |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
GUFICBIO Stock Price Comparison
Compare GUFICBIO with any stock or ETFCompare GUFICBIO with any stock or ETF
GUFICBIO
GUFICBIO Holdings
GUFICBIO Shareholdings
GUFICBIO Promoter Holdings Trend
GUFICBIO Promoter Holdings Trend
GUFICBIO Institutional Holdings Trend
GUFICBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding History
GUFICBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in GUFICBIO
Mutual Funds Invested in GUFICBIO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Gufic Biosciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4103% | Percentage of the fund’s portfolio invested in the stock 0.32% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 118/177 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5438% | Percentage of the fund’s portfolio invested in the stock 0.72% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 33/112 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3809% | Percentage of the fund’s portfolio invested in the stock 0.29% | Change in the portfolio weight of the stock over the last 3 months -0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 33/37 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GUFICBIO stock
smallcases containing GUFICBIO stock
Looks like this stock is not in any smallcase yet.
GUFICBIO Events
GUFICBIO Events
GUFICBIO Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GUFICBIO Dividend Trend
No dividend trend available
GUFICBIO Upcoming Dividends
GUFICBIO Upcoming Dividends
No upcoming dividends are available
GUFICBIO Past Dividends
GUFICBIO Past Dividends
Cash Dividend
Ex DateEx DateAug 28, 2026
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Aug 28, 2026
Cash Dividend
Ex DateEx DateSep 22, 2025
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2025
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 21, 2023
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 21, 2023
Cash Dividend
Ex DateEx DateAug 24, 2022
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Aug 24, 2022
GUFICBIO Stock News & Opinions
GUFICBIO Stock News & Opinions
Articles & Videos
Spotlight
Spotlight
Crisil Ratings reaffirmed Gufic BioSciences' credit ratings, increasing bank facilities to Rs. 516 CroreGufic BioSciences Ltd announced that Crisil Ratings Limited, a Credit Rating Agency, has reaffirmed its credit ratings on the company's bank facilities, totaling Rs. 516 Crore, which represents an enhancement from Rs. 425 Crore. The reaffirmed ratings include a long-term rating of CRISIL A-/ Stable and a short-term rating of CRISIL A2+, with no assignments, withdrawals, or changes to the ratings beyond the aforementioned enhancement of the total bank loan facilities; the rating agency did not mention any other instruments.
1 week agoCapital Market - Live
Corporate
Corporate
Gufic Biosciences invests up to USD 250,000 to form Gufic Philippines IncGufic Biosciences Limited announced that its board of directors approved the incorporation of a subsidiary, Gufic Philippines Inc., in the Philippines and an investment of up to USD 250,000, or its equivalent in Philippine Peso, to subscribe to its equity share capital, with the company proposing to hold approximately 99.99% of the subsidiary's equity.
1 month agoCapital Market - Live
Corporate
Corporate
Gu?c Biosciences shareholders to vote on director reappointment and auditor remunerationGu?c Biosciences Limited will seek shareholder approval at its 42nd Annual General Meeting on July 31, 2026, for two key resolutions. Shareholders will vote on an ordinary resolution to ratify the remuneration of the company’s Cost Auditor, requiring a simple majority. Additionally, a special resolution is slated for a vote to re-appoint Whole Time Director Pankaj Jayakumar Gandhi for a further five years, until September 6, 2031. A separate special resolution is also required due to Mr. Gandhi’s age, allowing him to continue serving past 70. Mr. Gandhi, son of Chairman & Managing Director Jayesh P. Choksi, holds no shares in the company and a detailed profile, including his experience and committee memberships, is available in Annexure A. Shareholders are reminded that special resolutions require a 75% majority to pass and must review all relevant documentation before casting their votes.
1 month agoCapital Market - Live
Corporate
Corporate
Gufic Biosciences to review quarterly financial results at a board meeting FridayGufic Biosciences Limited will hold a board meeting on Friday, August 14, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, according to a filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for equity shares of the company will remain closed for designated persons and their immediate relatives until 48 hours after the declaration of the financial results.
1 month agoCapital Market - Live
Corporate
Corporate
Gufic Biosciences' board re-appointed Pankaj Gandhi for five years, pending shareholder approvalGufic Biosciences Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its Board of Directors approved the re-appointment of Pankaj Jayakumar Gandhi as Whole Time Director for a further term of 5 years, effective September 07, 2026, to September 06, 2031, subject to shareholder approval at the 42nd Annual General Meeting.
1 month agoCapital Market - Live
Corporate
Corporate
Gufic Biosciences’ board re-appointed Pankaj Gandhi for a five-year termGufic Biosciences Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its board of directors approved the re-appointment of Pankaj Jayakumar Gandhi as Whole Time Director for a further term of 5 years, effective September 07, 2026, to September 06, 2031, subject to shareholder approval at the 42nd Annual General Meeting.
1 month agoCapital Market - Live
Earnings
Earnings
Gufic BioSciences consolidated net profit rises 183.68% in the March 2026 quarterNet profit of Gufic BioSciences rose 183.68% to Rs 21.90 crore in the quarter ended March 2026 as against Rs 7.72 crore during the previous quarter ended March 2025. Sales rose 22.83% to Rs 251.82 crore in the quarter ended March 2026 as against Rs 205.02 crore during the previous quarter ended March 2025. For the full year,net profit declined 7.81% to Rs 64.21 crore in the year ended March 2026 as against Rs 69.65 crore during the previous year ended March 2025. Sales rose 15.15% to Rs 944.01 crore in the year ended March 2026 as against Rs 819.81 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales251.82205.02 23 944.01819.81 15 OPM %18.7512.87 -16.0316.60 - PBDT36.6018.37 99 117.38115.21 2 PBT28.9510.52 175 86.5594.14 -8 NP21.907.72 184 64.2169.65 -8 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Board of Gufic BioSciences recommends final dividendGufic BioSciences announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.
3 months agoCapital Market - Live
Corporate
Corporate
Gufic BioSciences to discuss resultsGufic BioSciences will hold a meeting of the Board of Directors of the Company on 29 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Gufic BioSciences consolidated net profit declines 35.68% in the December 2025 quarterNet profit of Gufic BioSciences declined 35.68% to Rs 12.42 crore in the quarter ended December 2025 as against Rs 19.31 crore during the previous quarter ended December 2024. Sales rose 11.37% to Rs 231.41 crore in the quarter ended December 2025 as against Rs 207.79 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales231.41207.79 11 OPM %14.2516.33 - PBDT25.4130.88 -18 PBT17.7226.26 -33 NP12.4219.31 -36 Powered by Capital Market - Live
7 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant